ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

Nicotinate

HCID 937
反応を作成
印刷
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

標準SMILES
O=C([O-])c1cccnc1
InChIKey
PVNIIMVLHYAWGP-UHFFFAOYSA-M
分子式
C6H4NO2-
平均分子量
122.1 g/mol
単同位体質量
122.02420337

概要

Nicotinate is a pyridinemonocarboxylate that is the conjugate base of nicotinic acid, arising from deprotonation of the carboxy group; major species at pH 7.3. It has a role as a metabolite and a Saccharomyces cerevisiae metabolite. It is a vitamin B3 and a pyridinemonocarboxylate. It is a conjugate base of a nicotinic acid.

名称と識別子

優先名称
Nicotinate
IUPAC
pyridine-3-carboxylate

名称と別名

nicotinate3-pyridinecarboxylateCHEBI:32544RefChem:927733pyridine-3-carboxylatenico-400-PVNIIMVLHYAWGP-UHFFFAOYSA-MAC-907/25004509AE-848/01496050Q27104221

データベース識別子

PubChem CID
937
ChEBI
CHEBI:32544
Nikkaji
J239.335B

物性

構造計算による物性

XLogP
0.9
極性表面積
53 Ų
水素結合供与体数
0
水素結合受容体数
3
回転可能結合数
0
重原子数
9
形式電荷
-1
複雑度
108

実験および物理化学的性質

Collision Cross Section · 2 件

121 Ų [M-H]- [CCS Type: DT; Method: single field calibrated with ESI Low Concentration Tuning Mix (Agilent)]

124 Ų [M+H]+ [CCS Type: DT; Method: single field calibrated with Agilent tune mix (Agilent)]

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

毒性情報

TreatmentSupportive measures should be undertaken in the event of an overdose. (L1712)
Health Effects · 1 件

Niacin at extremely high doses can have life-threatening acute toxic reactions. Extremely high doses of niacin can also cause niacin maculopathy, a thickening of the macula and retina which leads to blurred vision and blindness. This maculopathy is reversible after stopping niacin intake. Side effects of hyperglycemia, cardiac arrhythmias and birth defects have also been reported. (A729)

Exposure RoutesOral (L1436) ; Intramuscular (L1436). Both nicotinic acid and nicotinamide are efficiently absorbed from the stomach and small intestine.
Toxicity Summary · 1 件

Niacin binds to Nicotinate D-ribonucleotide phyrophsopate phosphoribosyltransferase, Nicotinic acid phosphoribosyltransferase, Nicotinate N-methyltransferase and the Niacin receptor. Niacin is the precursor to nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP), which are vital cofactors for dozens of enzymes. The mechanism by which niacin exerts its lipid lowering effects is not entirely understood, but may involve several actions, including a decrease in esterification of hepatic triglycerides. Niacin treatment also decreases the serum levels of apolipoprotein B-100 (apo B), the major protein component of the VLDL (very low-density lipoprotein) and LDL fractions.

Signs and Symptoms · 1 件

Nicotinic acid can cause vasodilation of cutaneous blood vessels resulting in increased blood flow, principally in the face, neck and chest. This produces the niacin- or nicotinic acid-flush. The niacin-flush is thought to be mediated via the prostaglandin prostacyclin. Histamine may also play a role in the niacin-flush. Flushing is the adverse reaction first observed after intake of a large dose of nicotinic acid, and the most bothersome one.

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Toxicity DataLD50: 7000 mg/kg (Oral, Rat) (T14) LD50: 730 mg/kg (Intraperitoneal, Rat) (T14) LD50: 3500 mg/kg (Subcutaneous, Mouse) (T14)

化学と産業

薬理情報

Metabolism/Metabolites · 1 件

Niacin is rapidly metabolized and undergoes extensive first-pass metabolism in the liver. The drug is converted to several metabolites, including nicotinuric acid (NUA), nicotinamide, and nicotinamide adenine dinucleotide (NAD). At doses used to treat hyperlipoproteinemia, the principal metabolic pathways appear to be saturable, and niacin is thought to exhibit nonlinear, dose-dependent pharmacokinetics. (L1323) Half Life: 20-45 minutes.

MeSH Pharmacological Classification · 3 件

Substances that lower the levels of certain LIPIDS in the BLOOD. They are used to treat HYPERLIPIDEMIAS.

Drugs used to cause dilation of the blood vessels.

A group of water-soluble vitamins, some of which are COENZYMES.

用途と製造

Uses · 1 件

For the treatment of type IV and V hyperlipidemia. It is indicated as ajunctive therapy. It can be found in various foods, such as liver, chicken, beef, fish, cereal, peanuts and legumes. Niacin is also used as a pharmaceutical to reverse atherosclerosis. (A729)

関連反応

13 件
反応記録を作成
HRID 34899 の反応式
HRID 34899反応物として
HRID 34900 の反応式
HRID 34900反応物として
HRID 102188 の反応式
HRID 102188生成物として
HRID 295972 の反応式
HRID 295972生成物として
HRID 324688 の反応式
HRID 324688生成物として
HRID 341516 の反応式
HRID 341516反応物として
HRID 376482 の反応式
HRID 376482反応物として
HRID 602234 の反応式
HRID 602234反応物として
前へ1 / 2 ページ

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート